# Greg Bailey > Greg Bailey is a Series A investor at Denim (London) backing Biotechnology and Pharmaceutical. See 10 investments, check sizes, portfolio. Updated Aug 2026. - Type: Angel Investor - Fund: [Denim](https://shizune.co/investors/profile/denim) - Location: London, United Kingdom - Total investments: 10 - Last investment: Mar 2026 - Lead investor: 50% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/gbaileycom - X (Twitter): https://twitter.com/gbpalantir Greg Bailey is a Series A investor at Denim in London focused on Biotechnology and Pharmaceutical. Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director andco-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years. ## Round sizes | Stage | Round size | | --- | --- | | Series A | $3M–$19M | | Post-IPO Equity | $15M–$80M | ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 6 | 60% | | Pharmaceutical | 4 | 40% | | Health Care | 3 | 30% | | Medical | 2 | 20% | | Biopharma | 2 | 20% | 10 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series A | 2 | 20% | | Post-IPO Equity | 2 | 20% | | Seed | 1 | 10% | | Funding Round | 1 | 10% | | Post-IPO Debt | 1 | 10% | 7 stages tracked in total. ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 5 | 50% | | Isle of Man | 1 | 10% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Serina Therapeutics | Serina Therapeutics is a privately-held pharmaceutical company that is advancing novel therapeutics for cancer, inflammation, pain, and metabolic disorders using its proprietary polymer technology. They have created new pharmaceutical candidates using polyoxazoline (POZ), a safe, water-soluble polymer to which they can attach a variety of smallmolecules, proteins, peptides, and DNA. The attachment of these molecules to polymers of POZ typically confers a unique pharmacokinetic profile that is markedly different from the parent compound, and this profile may confer advantages in terms of safety and efficacy. | $15M | Post-IPO Equity | Mar 18, 2026 | | | Serina Therapeutics | Serina Therapeutics is a privately-held pharmaceutical company that is advancing novel therapeutics for cancer, inflammation, pain, and metabolic disorders using its proprietary polymer technology. They have created new pharmaceutical candidates using polyoxazoline (POZ), a safe, water-soluble polymer to which they can attach a variety of smallmolecules, proteins, peptides, and DNA. The attachment of these molecules to polymers of POZ typically confers a unique pharmacokinetic profile that is markedly different from the parent compound, and this profile may confer advantages in terms of safety and efficacy. | | Post-IPO Debt | Sep 09, 2025 | | | LyGenesis | LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD). | $19M | Series A | Oct 24, 2023 | | | MDI Therapeutics | MDI Therapeutics is an operator of a discovery stage company focused on developing novel therapies for fibrotic diseases. The company have developed a proprietary discovery platform which has successfully identified novel small molecule and protein drug candidates, and have advanced these programs through key translational experiments usingclinical biomarkers. | $9M | Series A | Mar 02, 2022 | | | LyGenesis | LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD). | $11M | Convertible Note | Dec 30, 2020 | | | LyGenesis | LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD). | $4M | Debt Financing | Oct 21, 2019 | | | LyGenesis | LyGenesis is an organ regeneration company enabling a patient's own lymph nodes to be used as bioreactors to regrow functioning ectopic organs. Their initial target organ for clinical development is liver regeneration, with a focus on helping patients with end stage liver disease (ESLD). | $3M | Series A | May 09, 2018 | | | Juvenescence | Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity. Juvenescence has raised $111M to build an ecosystem and pipeline of assets targeting aging, age-related disease, and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development oftherapeutics that meaningfully extend human healthspan and eventually lifespan. A meaningful increase in lifespan in the already aging world will have profound implications on all sectors of society, and in particular healthcare, education, insurance, and leisure.The company creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions. Their work is based on a novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging.Juvenescence's goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence. | $12.3M | Seed | Jan 08, 2018 | | | Bristol-Myers Squibb | Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. | $80M | Post-IPO Equity | Feb 21, 2017 | | | Biohaven Pharmaceutical | Biohaven is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipelineproducts include BHV3000-301, BHV3000-302, BHV3000-303, and others. | $80M | | Nov 01, 2016 | | 10 of 10 investments shown. ## Co-investors - [Aisling Capital](https://shizune.co/investors/profile/aisling-capital) — VC Fund, 2 deals together - [Aperture Venture Partners](https://shizune.co/investors/profile/aperture-venture-partners) — VC Fund, 2 deals together - [Longevity Vision Fund](https://shizune.co/investors/profile/longevity-vision-fund) — VC Fund, 2 deals together - [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 2 deals together - [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 2 deals together - [Apeiron Investment Group](https://shizune.co/investors/profile/apeiron-investment-group) — VC Fund, 1 deal together ## About Denim VC Fund 1 contacts available at Denim. | Name | Title | Profile | | --- | --- | --- | | Greg Bailey | CEO & Founder | https://shizune.co/investors/profile/greg-bailey | ## Similar investors ### Similar industry - [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund - [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund - [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund ### Similar stage - [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund ### Similar country - [Blockchain Founders Fund](https://shizune.co/investors/profile/blockchain-founders-fund) — VC Fund - [Force Over Mass Capital](https://shizune.co/investors/profile/force-over-mass-capital) — VC Fund - [NewBound Venture Capital](https://shizune.co/investors/profile/excelsior-financial-partners) — VC Fund ## Featured in investor lists - [All Investors in Isle of Man](https://shizune.co/investors/investors-isle-of-man) - [All Angel Investors in Isle of Man](https://shizune.co/investors/angel-investors-isle-of-man) - [Biotech Investors in Isle of Man](https://shizune.co/investors/biotech-investors-isle-of-man) - [Health Care Angel Investors in Ireland](https://shizune.co/investors/health-care-angel-investors-ireland) ## FAQ ### What does Greg Bailey invest in? Greg Bailey invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Post-IPO Equity stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### What is Greg Bailey's check size? Greg Bailey typically joins rounds of $3M–$19M at Series A and $15M–$80M at Post-IPO Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Greg Bailey participates in. ### When did Greg Bailey last invest? The most recent investment recorded for Greg Bailey closed in Mar 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co